Pakistan has become an important destination and a key focus for Chinese pharmaceutical companies to expand their market along the "Belt and Road". China-Pakistan pharmaceutical cooperation is not only limited to trade, but also has great potential for technology transfer and investment cooperation in the future.
China-Pakistan Drug Regulatory and Industry Cooperation Online Communication Meeting was held by video on January 25, 2022, with Khalid Mansoor, Special Assistant to the Prime Minister of Pakistan for Corridor Affairs, Xie Guoxiang, Minister Counselor of the Economic and Commercial Office of the Chinese Embassy in Pakistan, Luo Xiaomei, Deputy Director General of Asia Department of the Ministry of Commerce, Asim Rauf, Director General of the Pakistan Drug Regulatory Authority, and Meng Dongping, Secretary of the Party Committee of the China Chamber of Commerce for Import and Export of Medicines and Health Products attended the meeting and delivered a speech. Director Jiang Lu of the Department of Science and Technology and International Cooperation of China Drug Administration and Dr. Fakhruddin of the Pakistan Drug Administration made policy interpretation on behalf of the regulatory agencies of both sides.
More than 300 representatives of pharmaceutical companies from China and Pakistan attended the conference online. Mr. Liang Jian, Chairman of Pharmacare, was invited to speak online and participate in the discussion as an industry representative.
At the meeting, China State Drug Administration and Pakistan Drug Supervision Bureau introduced the latest progress of China´s drug review and approval reform and international convergence and Pakistan´s drug regulatory system and the latest policy on imported drugs. Meng Dongping, Party Secretary of China Chamber of Commerce for Import and Export of Medicines and Health products, made an important speech on the progress and opportunities of China-Pakistan pharmaceutical industry cooperation.
Asim Rauf, Director General of the Pakistan Drug Regulatory Authority, said that the Pakistani side has a series of policy incentives to support the development and investment in the pharmaceutical industry in terms of manpower, logistics and tariffs. During the epidemic, China and Pakistan worked closely together and several vaccines were launched in clinical trials in Pakistan. The cooperation between China and Pakistan in the vaccine and pharmaceutical industry has opened a new chapter of cooperation between China and Pakistan in the field of medicine. China is Pakistan's largest trading partner and the largest supplier of APIs, and with rapid technological development, future cooperation between China and Pakistan in the pharmaceutical sector is full of potential.
In his speech, Secretary Meng Dongping, Director of PA Drug Administration, said that the future cooperation between China and Pakistan in the field of medicine is very large, at present, China's exports of APIs to Pakistan account for a relatively large proportion, and the next step the two sides can gradually expand from APIs and generic drugs to vaccines, innovative drugs, medical devices, traditional Chinese medicine, nutrition and health and many other fields, presented in a variety of ways such as international trade, technology transfer and investment cooperation.
Mr. Liang Jian, Chairman of Nanjing Pharmacare Pharmaceutical Technology Co., Ltd. shared his views on the international progress of Chinese innovative drugs and cooperation with Pakistan and some experiences and problems in carrying out the cooperation between China and Pakistan in pharmaceutical industry.
Mr. Liang pointed out that Pharmacare, as a bridge of cooperation between Chinese and foreign famous pharmaceutical enterprises, has achieved milestones. At present, the export of pharmaceutical preparations ranks top ten in China and the export of plasma products ranks first in China.
As a professional pharmaceutical trade and regulatory technical consulting service provider, Pharmacare provides one-stop service from quality standard improvement, GMP certification, CTD document writing, international registration to international sales of pharmaceutical products. We have a long-term presence in emerging markets (e.g. Brazil, Thailand), accelerated regulatory markets (e.g. EU, Australia), and a long-term plan in Pakistan.
In the past decades, many Chinese pharmaceutical APIs and formulations have been exported to Pakistan, mainly basic antibiotics, basic I.V. fluids, antineoplastics and biologics that have been on the market for many years. With the reform of China's drug review and approval, more and more drugs are expected to be on par with international standards. In 2021 alone, eight domestic innovative drugs have been accepted by FDA for NDA (New Drug Application) or BLA (Biologics License Application) in China.
Nanjing Pharmacare sincerely hopes to work with pharmaceutical colleagues to leverage the development of the pharmaceutical industry, seize the historical opportunity of the Belt and Road, and start a new journey of China-Pakistan pharmaceutical cooperation, focusing on generic drugs, biosimilars and innovative drugs with technical barriers, not only providing products but also supporting technology transfer to local production, so as to provide local doctors and patients in Pakistan with more, better and better drug choices.
Japanese
Chinese
Spanish